In recent years the management of non-muscle-invasive bladder cancer has undergone radical changes. Intravesical Bacillus Calmette-Guérin (BCG) has long been established as the therapeutic standard ...
NCCN now includes Anktiva plus BCG for BCG-unresponsive papillary-only NMIBC, acknowledging an unmet need in patients without CIS who have limited post-BCG options. Radical cystectomy remains ...
A review of studies including 20,000 patients with NMIBC highlights the need for individualized NMIBC management that balances oncologic control with QoL and patient-reported outcomes. Frequent ...
PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the first patient in the United States with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder ...
"Medical Journeys" is a set of clinical resources reviewed by doctors, meant for physicians and other healthcare professionals as well as the patients they serve. Each episode of this journey through ...
A multicenter, open-label phase 1/2 study of TYRA-300 in advanced urothelial carcinoma and other solid tumors with activating FGFR3 alterations (SURF301). Background: Response rates (55-65%) with ...
Long-term results of a phase 2 study of neoadjuvant chemotherapy combined with tislelizumab followed by radiotherapy for bladder-preserving treatment in selected high-risk/locally advanced muscle ...
ImmunityBio Inc. IBRX shares are up Tuesday following the announcement that the National Comprehensive Cancer Network (NCCN) has updated its Clinical Practice Guidelines in Oncology for Bladder Cancer ...
After matching, standardized mean differences were <0.1 for all key covariates. NAI + BCG showed improved outcomes versus other bladder sparing therapies in the d-uo cohort, including increased ...
ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results